X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (53) 53
oncology (50) 50
humans (47) 47
male (35) 35
middle aged (35) 35
aged (33) 33
female (33) 33
article (31) 31
lung neoplasms - drug therapy (25) 25
lung neoplasms - pathology (24) 24
aged, 80 and over (23) 23
adult (22) 22
lung neoplasms - genetics (21) 21
mutation (21) 21
respiratory system (20) 20
lung cancer (19) 19
neoplasm staging (19) 19
carcinoma, non-small-cell lung - drug therapy (16) 16
chemotherapy (15) 15
cancer (14) 14
lung neoplasms - mortality (13) 13
treatment outcome (13) 13
adenocarcinoma - genetics (12) 12
carcinoma, non-small-cell lung - pathology (12) 12
immunotherapy (12) 12
prognosis (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
neoadjuvant therapy (11) 11
tumors (11) 11
adenocarcinoma - pathology (10) 10
adenocarcinoma of lung (10) 10
docetaxel (10) 10
erbb receptors - genetics (10) 10
lung cancer, non-small cell (10) 10
nivolumab (10) 10
open-label (10) 10
survival (10) 10
antineoplastic agents - therapeutic use (9) 9
carcinoma, non-small-cell lung - mortality (9) 9
gefitinib (9) 9
hematology, oncology and palliative medicine (9) 9
therapy (9) 9
adjuvant chemotherapy (8) 8
egfr (8) 8
multicenter (8) 8
non-small cell lung cancer (8) 8
surgery (8) 8
trial (8) 8
antibodies, monoclonal - therapeutic use (7) 7
carcinoma, non-small-cell lung - genetics (7) 7
cell lung-cancer (7) 7
gene expression (7) 7
lung neoplasms - surgery (7) 7
lung neoplasms - therapy (7) 7
pembrolizumab (7) 7
pulmonary and respiratory medicine (7) 7
adenocarcinoma (6) 6
care and treatment (6) 6
lung adenocarcinoma (6) 6
nsclc (6) 6
patients (6) 6
preoperative chemotherapy (6) 6
pulmonary/respiratory (6) 6
resistance (6) 6
survival analysis (6) 6
young adult (6) 6
adenocarcinoma - drug therapy (5) 5
adenocarcinoma - mortality (5) 5
afatinib (5) 5
antibodies, monoclonal - adverse effects (5) 5
bevacizumab (5) 5
carcinoma, non-small-cell lung - surgery (5) 5
chemotherapy, adjuvant (5) 5
induction chemotherapy (5) 5
ipilimumab (5) 5
lung neoplasms - diagnosis (5) 5
medical colleges (5) 5
neoadjuvant chemotherapy (5) 5
non-small-cell lung cancer (5) 5
original reports (5) 5
phase-ii trial (5) 5
protein kinase inhibitors - therapeutic use (5) 5
proto-oncogene proteins - genetics (5) 5
ras proteins - genetics (5) 5
receptor protein-tyrosine kinases - genetics (5) 5
vinorelbine plus cisplatin (5) 5
abridged index medicus (4) 4
adenocarcinomas (4) 4
apoptosis (4) 4
b7-h1 antigen - antagonists & inhibitors (4) 4
b7-h1 antigen - immunology (4) 4
cancer therapies (4) 4
carboplatin (4) 4
carcinoma, non-small-cell lung - therapy (4) 4
cardiac & cardiovascular systems (4) 4
cell biology (4) 4
drug resistance, neoplasm (4) 4
erlotinib (4) 4
follow-up studies (4) 4
health aspects (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Radiotherapy and Oncology, ISSN 0167-8140, 03/2020, Volume 144, pp. 101 - 104
Durvalumab after concurrent chemoradiation has significantly improved survival in stage III non-small cell lung cancer (NSCLC). However, there is limited data... 
Consolidative durvalumab | Chemoradiation | Non-small cell lung cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. TPS8581 - TPS8581
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 2546 - 2546
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 299 - 308
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. 8068 - 8068
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 04/2016, Volume 11, Issue 4, pp. 537 - 544
Although perioperative chemotherapy improves survival in patients with resectable lung cancers, systemic recurrence remains common. Neoadjuvant chemotherapy... 
Neoadjuvant therapy | Non–small cell lung cancer | Adaptive clinical trial | 18F-FDG PET | F-FDG PET | Non-small cell lung cancer | non-small cell lung cancer | 18FDG-PET
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. 8536 - 8536
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. e19002 - e19002
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 21, pp. 1976 - 1986
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. 8067 - 8067
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. 7548 - 7548
Journal Article
Nature Genetics, ISSN 1061-4036, 02/2019, Volume 51, Issue 2, pp. 202 - 206
Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers, but predictive biomarkers are needed. Findings in selected cancer... 
CTLA-4 BLOCKADE | THERAPY | LANDSCAPE | PD-1 BLOCKADE | GENETICS & HEREDITY | SENSITIVITY | NEOANTIGENS | Usage | Research | Gene mutations | Immunotherapy | Oncology, Experimental | Cancer | Laboratories | Lung cancer | Melanoma | Histology | Metastasis | Gene expression | Cancer therapies | Patients | Survival | Metastases | Next-generation sequencing | Immune checkpoint | Biomarkers | Mutation | Tumors
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. 7515 - 7515
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.